Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors

(2015) Christine M. Fillmore et al.   NATURE

EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non-Small Cell Lung Carcinoma

(2013) C. Behrens et al.   CLINICAL CANCER RESEARCH

Targeting histone modifications—epigenetics in cancer

(2013) Tanja Waldmann et al.   CURRENT OPINION IN CELL BIOLOGY

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

(2013) M-C Chen et al.   Cell Death & Disease

Pre-Clinical Studies of Epigenetic Therapies Targeting Histone Modifiers in Lung Cancer

(2013) Kenneth Huffman et al.   Frontiers in Oncology

Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells

(2012) W. Fiskus et al.   CLINICAL CANCER RESEARCH

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells

(2012) Junko Kikuchi et al.   LUNG CANCER

Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer

(2011) Huqun et al.   CANCER

EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes  -Catenin-Dependent Hepatocarcinogenesis

(2011) A. S. L. Cheng et al.   CANCER RESEARCH

EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

(2011) Jean-Charles Soria et al.   CANCER TREATMENT REVIEWS

Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy

(2011) C. D. Kemp et al.   CLINICAL CANCER RESEARCH

Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung

(2011) Yoshihiro Minamiya et al.   LUNG CANCER

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

(2011) Francesco Crea et al.   Molecular Cancer

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

(2010) Nina Wagener et al.   BMC CANCER

S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition

(2010) Annette Hayden et al.   BREAST CANCER RESEARCH AND TREATMENT

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance

(2010) Junko Kikuchi et al.   CANCER

Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study

(2010) Anne M. Traynor et al.   Journal of Thoracic Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

(2009) W. Fiskus et al.   BLOOD

EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance

(2009) M.-L. Suva et al.   CANCER RESEARCH

Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma

(2009) Junpei Yamaguchi et al.   CANCER SCIENCE

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation

(2009) T. B. Miranda et al.   MOLECULAR CANCER THERAPEUTICS

DACT3 Is an Epigenetic Regulator of Wnt/β-Catenin Signaling in Colorectal Cancer and Is a Therapeutic Target of Histone Modifications

(2008) Xia Jiang et al.   CANCER CELL

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model

(2008) A. Miyanaga et al.   MOLECULAR CANCER THERAPEUTICS

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA